BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 27664101)

  • 1. Natural course of mild Graves' orbitopathy: is it a chronic remitting or a transient disease?
    Anagnostis P; Boboridis K; Adamidou F; Kita M
    J Endocrinol Invest; 2017 Mar; 40(3):257-261. PubMed ID: 27664101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.
    Tanda ML; Piantanida E; Liparulo L; Veronesi G; Lai A; Sassi L; Pariani N; Gallo D; Azzolini C; Ferrario M; Bartalena L
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1443-9. PubMed ID: 23408569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
    Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal management of Graves orbitopathy: a multidisciplinary approach.
    Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
    Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Graves' orbitopathy].
    Balázs C
    Orv Hetil; 2006 Jun; 147(22):1011-7. PubMed ID: 16913090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and natural history of Graves' orbitopathy in the XXI century.
    Piantanida E; Tanda ML; Lai A; Sassi L; Bartalena L
    J Endocrinol Invest; 2013 Jun; 36(6):444-9. PubMed ID: 23587873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
    Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
    Batra R; Krishnasamy SK; Buch H; Sandramouli S
    Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of biological sex, age and smoking on Graves' orbitopathy - a ten-year tertiary referral center analysis.
    Oeverhaus M; Winkler L; Stähr K; Daser A; Bechrakis N; Stöhr M; Chen Y; Eckstein A
    Front Endocrinol (Lausanne); 2023; 14():1160172. PubMed ID: 37082130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy.
    Le Moli R; Muscia V; Tumminia A; Frittitta L; Buscema M; Palermo F; Sciacca L; Squatrito S; Vigneri R
    Nutr Metab Cardiovasc Dis; 2015 May; 25(5):452-7. PubMed ID: 25746910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum selenium status in Egyptians patients who had Graves' disease with and without ophthalmopathy.
    Hasanin GA; Mohamed MS; Maher MM; Ahmed AM; ALi HM; Mansour HK
    Egypt J Immunol; 2024 Jan; 31(1):133-142. PubMed ID: 38224470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraocular pressure and superior ophthalmic vein blood flow velocity in Graves' orbitopathy: relation with the clinical features.
    Konuk O; Onaran Z; Ozhan Oktar S; Yucel C; Unal M
    Graefes Arch Clin Exp Ophthalmol; 2009 Nov; 247(11):1555-9. PubMed ID: 19609549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.
    Li HX; Xiang N; Hu WK; Jiao XL
    J Endocrinol Invest; 2016 Nov; 39(11):1225-1233. PubMed ID: 27220843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
    Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total thyroid ablation in Graves' orbitopathy.
    Menconi F; Leo M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2015 Aug; 38(8):809-15. PubMed ID: 25740065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.
    Perros P; Žarković M; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi A; Bournaud C; Brix TH; Covelli D; Ćirić S; Daumerie C; Eckstein A; Fichter N; Führer D; Hegedüs L; Kahaly GJ; Konuk O; Lareida J; Lazarus J; Leo M; Mathiopoulou L; Menconi F; Morris D; Okosieme O; Orgiazzi J; Pitz S; Salvi M; Vardanian-Vartin C; Wiersinga W; Bernard M; Clarke L; Currò N; Dayan C; Dickinson J; Knežević M; Lane C; Marcocci C; Marinò M; Möller L; Nardi M; Neoh C; Pearce S; von Arx G; Törüner FB
    Br J Ophthalmol; 2015 Nov; 99(11):1531-5. PubMed ID: 25953846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy.
    Marcocci C; Marinò M
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):325-37. PubMed ID: 22632369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.
    Perros P; Hegedüs L; Bartalena L; Marcocci C; Kahaly GJ; Baldeschi L; Salvi M; Lazarus JH; Eckstein A; Pitz S; Boboridis K; Anagnostis P; Ayvaz G; Boschi A; Brix TH; Currò N; Konuk O; Marinò M; Mitchell AL; Stankovic B; Törüner FB; von Arx G; Zarković M; Wiersinga WM
    Orphanet J Rare Dis; 2017 Apr; 12(1):72. PubMed ID: 28427469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.